Upgrade to SI Premium - Free Trial

Amgen's (AMGN) Repatha Pushtronex System Receives FDA Approval

July 11, 2016 9:03 AM
Amgen (Nasdaq: AMGN) announced that the U.S. Food and Drug Administration (FDA) has approved the Repatha (evolocumab) Pushtronex system (on-body ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Corporate News FDA Management Comments

Next Articles